Kornimate/medical-research-clean huggingface dataset:
examination of nurses' use of broselow tape in non-resuscitation pediatric emergency department practices

Conditions: Pediatric

Summary: the patient's body weight is often taken as a basis when calculating drug doses and determining equipment sizes for pediatric patients presenting to the emergency department. the methods used to determine body weight are the family's estimated weight, formulas for estimating weight according to age, or the broselow band used to estimate weight according to height. weight estimates that are incomplete compared to the child's actual body weight lead to medication errors, wrong material selection and prolongation of the procedure, resulting in increased mortality and morbidity.

this study will be carried out to create an evidence-based practice in the selection of catheters to be used during peripheral intravenous catheter insertion, urinary catheter insertion, nasogastric/orogastric catheter insertion and aspiration in children using the broselow band in non-resuscitation applications coming to the pediatric emergency department. by using the boselow band in non-resuscitation pediatric emergency department applications, reducing the number of attempts and errors by ensuring the correct equipment selection in the procedures applied to patients, and increasing the success of the procedure; this will be done to ensure that the decisions taken by nurses using their experience and previous knowledge are more systematic.

Eligibility criteria:
inclusion criteria: * children weighing 3 to 36 kg and 47 to 143 cm tall * children aged 0-18 * patients coming to the emergency department for non-resuscitation procedures * patients and their families who volunteer to participate in the research * patients who will have a peripheral intravenous catheter inserted * patients who will have a urinary catheter inserted * patients who will have a nasogastric/orogastric catheter inserted * patients who will undergo aspiration procedure exclusion criteria: * children weighing less than 3 kg and taller than 143 cm * children with anomaly contractures that may prevent measurement during measurement with the broselow tape * patients with central venous catheter * patients with peripheral intravenous catheters outside the pediatric emergency department * patients who have a urinary catheter inserted outside the pediatric emergency department * patients who have a nasogastric/orogastric catheter inserted outside the pediatric emergency department

Keywords: broselow tape pediatric emergency department nurse
emergent therapies in obp. pilot study

Conditions: Neonatal Brachial Plexus Palsy

Summary: obstetric brachial palsy (obp) produces functional limitations in the involvement of the affected upper limb within the child's natural environment. the therapeutic interventions of conventional mirror therapy (mt) and mirror therapy virtual reality (vr) are aimed at the rehabilitation of the affected upper limb and the quality life improvement. to quantify the increase in the affected upper limb spontaneous use and the quality of life of children with upper obp from 6-12 years, when they are treated with conventional mt or mirror therapy vr applying specific protocol: 20 min/day in 4 weeks.

the intervention protocol was permorfed for four weeks, three days per week applying conventional mirror therapy or mirror therapy virtual reality, with 20-minute sessions in 4 weeks. designed to be done at home. two measurements of the affected upper limb spontaneous use and quality of life were performed, a pre-treatment assessment corresponding to the baseline situation, and another post-treatment assessment to observe the results after the therapy.

Eligibility criteria:
inclusion criteria: * ages between 6 and 12 years old, upper obstetric brachial palsy type erb-duchenne (c5-c6) and extended erb-duchenne (c5-c7), preserved functionality to do the activities, adequate cognitive level to follow the proposed activities. exclusion criteria: * associated pathologies, medical complications or cognitive and / or visual impairment that prevent the activities performance, affected upper limb surgeries in the last year, treatment with botulinum toxin in the last three months, no possession of a device with android operating system for the application of virtual reality therapy, families and children no partners.

Keywords: virtual reality. family mirror therapy obstetrical brachial palsy upper extremity
clinical observational registry of patients with left bundle branch block

Conditions: Left Bundle Branch Block (LBBB) on ECG

Summary: the electromechanical dyssynchrony induced by the presence of lbbb is in some patients, but not all, the cause of progressive left ventricular systolic dysfunction and heart failure. aims 1. to investigate the clinical, ecg, imaging-derived features in a large cohort of patients affected by lbbb on ecg. 2. to identify predictors of lbbb-induced lv systolic dysfunction and predictors of outcome in this population. 3. to derive data which may have an impact on therapeutic management.


Eligibility criteria:
inclusion criteria: * lbbb on ecg exclusion criteria: * previous extensive anterior myocardial infarction * previous cardiac surgery or transcatheter aortic valve implantation (tavi) * congenital structural heart disease * patients implanted with permanent right ventricular stimulation devices and permanent pacing * denial to consent
a study on predictive models and clinical outcome of radiation pneumonitis

Conditions: Radiation Pneumonitis

Summary: radiation pneumonitis is the main dose-limiting toxicity of thoracic radiotherapy, which can affect life quality, survival, and the tumor-controlling effects of patients receiving thoracic radiotherapy. the purpose of this study is to: * identify biomarkers including serum proteins, gene expression, genetic changes, and epigenetic modifications that determine radiation pneumonitis. * investigate the relationship between radiation pneumonitis and other toxicities induced by radiotherapy. * construct a predictive model for radiation pneumonitis. * evaluate survival and treatment outcome of patients with radiation pneumonitis.

1. collect clinical information, ct images, and peripheral blood of the lung cancer patients treated with thoracic radiotherapy in tongji hospital, hubei cancer hospital, and jingjiang people's hospital. 2. follow up the enrolled patients. all patients enrolled in this study are examined during and one month after radiotherapy. then, the patients are followed every three months for the first year and every six months thereafter. at each follow-up visits, all patients are asked to undergo a chest ct, and information including survival status, symptoms, ct images, and treatment is collected. radiation pneumonitis and other toxicities induced by radiotherapy are graded by two radiation oncologists according to the common terminology criteria for adverse events 4.0 (ctcae4.0). 3. detect serum proteins, gene expression profile, single-nucleotide polymorphisms, and epigenetic modifications that may be associated with radiation pneumonitis. 4. screen biomarkers that are associated with radiation pneumonitis via univariate and multivariate cox regression analysis. 5. construct a predictive model of radiation pneumonitis based on clinical information, radiomics, and biomarkers via machine learning or least absolute shrinkage and selection operator. 6. use kaplan-meier and cox model to analyze the association of radiation pneumonitis with survival and efficacy of antitumor treatment. 7. identify biomarkers and predictors of other toxicities induced by radiotherapy including radiation esophagitis, cardiotoxicity and radiodermatitis.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of lung cancer by histology 2. radiation dose at least 45 gy 3. karnofsky \>60 4. age\>18 5. life expectancy of at least 6 months exclusion criteria: 1. previous thoracic irradiation 2. severe cardiopulmonary diseases
flu vaccine response in patients on biologic therapies

Conditions: Rheumatologic Disorder; Inflammatory Bowel Diseases; Immune Complex Diseases

Summary: this proposed study will assess the immunogenicity, safety, and clinical efficacy of an influenza vaccine booster dose strategy in patients with autoimmune diseases who are receiving immunosuppressive therapies. investigators will compare serologic responses to single versus a booster dose of influenza vaccine in patients with inflammatory bowel disease (ibd- crohn's disease or ulcerative colitis) or rheumatologic diseases who are receiving immunosuppressive therapies. subjects will be randomized to receive either one or two doses of influenza vaccination in year #1. in year# 2, all participants will be given two doses of influenza vaccine. serologic responses will be measured pre and 4-6 weeks post vaccination. this study will also assess the immunogenicity and safety of a booster vaccine strategy in the prevention of influenza-like illness (ili). investigators anticipate that booster dose strategy will improve both clinical and serologic responses in this vulnerable population.


Eligibility criteria:
inclusion criteria: * children ages 3-22 years * rheumatologic condition (jia, uveitis, sle and other rheumatologic disorders) or inflammatory bowel disease (crohn's disease or ulcerative colitis) and who are receiving immunosuppressive therapies as follows: * tnf inhibitors \[etanercept (enbrel), adalimumab (humira®), infliximab (remicade®)\] * anti il -1 \[anakinra (kineret®) or canakinumab (ilaris®)\] * il-6 tocilizumab (actemra®) * anti il-12/23 ustekinumab (stelara®) * anti ctla-4 \[abatacept (orencia®)\] * vedolizumab (entyvio®) * azathioprine (imuran®) * 6 mercaptopurine (purinethol®) * cyclosporine * leflunomide * mycophenolate * methotrexate (otrexup® or rasuvo®) exclusion criteria: * prior allergic reaction to any vaccine components * other contraindication to influenza vaccination * severe egg allergy * pregnancy * prior guillain-barre syndrome * therapy with oral corticosteroids ≥2 mg/mg/day within 4 weeks of study entry * prior rituximab * prior cyclophosphamide * prior ivig within 8 weeks * acute febrile illness at time of study evaluation * no prior history of two doses of influenza in the past for ages 3-8 years

Keywords: influenza vaccine booster dose immunocompromised biologic therapy rheumatologic disease inflammatory bowel disease
hierarchical treatment based on somatization symptom checklist

Conditions: Syndrome X

Summary: a comparative study is conducted on the patients with suspected coronary artery disease (cad). the patient will undergo coronary angiography after a somatic symptom scale (sss) survey is carried out combining with patient health questionnaire (phq-9) and generalized anxiety disorder 7-items (gad-7). patient is then treated according to the checklist score and coronary angiography result. the efficacy, sensitivity and specificity of the sss checklist will be evaluated during following up.

the presentation of physical complaints such as chest discomfort suggestive of suspicious coronary artery disease (cad) but remain unexplained after negative finding from coronary angiography represents one of the most frustrating and puzzling problems in clinical medicine.a comparative study is conducted on the patients with suspected coronary artery disease. a somatic symptom scale (sss) survey is carried out combining with patient health questionnaire (phq-9) and generalized anxiety disorder 7-items (gad-7). patient is treated according to the checklist score and coronary angiography result. three surveys will be re-conducted 2 weeks after treatment. the sensitivity and specificity of the sss checklist will be evaluated during following up.

Eligibility criteria:
inclusion criteria: * patients with suspected coronary artery disease exclusion criteria: * patients who have lost their self assessments of capacity. * patients who have been previously confirmed serious mental disorders. * patients who is taking anti-anxiety agents or anti-depression agents.

Keywords: somatization symptom score sss checklist coronary angiography patient health questionnaire generalized anxiety disorder 7-items
effects of levetiracetam monotherapy on various hematological parameters in adult patients suffering of epilepsy

Conditions: Neutropenia; Thrombocytopenia; Aplastic Anemia; Anemia; Epilepsy

Summary: low therapeutic index of established antiepileptic drugs (aeds) coupled with better understanding of the pathophysiology of seizure has encouraged the development of several novel aeds. the conventional antiepileptics like phenytoin, phenobarbitone, valproate and carbamazepine and newer antiepileptics like levetiracetam. are used for epilepsy. aeds induce potentially toxic effects over a period of time which remains undetermined over very long time. earlier studies in this regard, states uneven results about hematological (hb%, blood cell count etc.) toxicity of aeds.

epilepsy is a chronic neurologic disease that is considered the most common neurological diseases in the world and comes third after cerebrovascular and alzheimer's disease. epilepsy is a disorder characterized by a long-term tendency to cause epileptic seizures due to abnormal electrical activity in the brain with neurological, cognitive, psychological and social consequences . however, it is not a single disease entity but it is a collection of different kinds of seizures resulting from several mechanisms and different cause. the aim of epilepsy management is complete seizures cessation and maintenance of a good quality of life, which is affected not only by the epileptic attacks but also by the adverse effect of the drugs used .levetiracetam (lev) is a relatively new, broad-spectrum aed that has seen extensive use during recent years . its mechanism of action is not completely known, but differs from those of other aeds. lev is described as being well tolerated, and the most common adverse effects are generally mild . studies evaluating the effect of levetiracetam on hematological parameters have reported a spectrum of hematological abnormalities that ranges from mild thrombocytopenia or neutropenia to anemia, red cell aplasia, until bone marrow failure. fortunately, potentially fatal hematological disorders such as aplastic anemia are very rare.

Eligibility criteria:
inclusion criteria: adult epileptic patients of both genders aged \>18 years on mono-therapy of levetiracetam anti-epileptic drug treatment for at least six months. exclusion criteria: 1. patients were on treatment for less than six months. 2. patients had other conditions besides epilepsy that could affect blood parameters. 3. patients on treatment with other antiepileptic medications besides levetiracetam.

Keywords: levetiracetam hematological effects antiepileptic drugs epilepsy neutropenia thrombocytopenia
the efficacy and safety of chlorhexidine gluconate chip (periochip®) in therapy of peri-implantitis

Conditions: Peri-Implantitis

Summary: the objective of the study is to assess the efficacy and safety of periochip® (chlorhexidine gluconate chip) in the treatment of patients with peri-implantitis. the hypothesis of the study is that periochip® in adjunct to mechanical subgingival debridement is more effective in the treatment of peri-implantitis when compared to the common method of mechanical subgingival debridement alone. the primary efficacy measure will be the reduction in probing pocket depth at 6 months as measured at sites of qualifying target implant.

this is a research study that uses the drug periochip® (active ingredient chlorhexidine gluconate) as an experimental treatment for "periimplantitis". this condition is defined an inflammation affecting the tissues (gums and bone) around an already stable implant, resulting in loss of supporting jaw bone. it is caused by many factors but current research links the condition with the presence of bacteria in the mouth which are responsible for periodontitis (gum disease). if left untreated, this can lead to decreased bone support, weakening of the implant and potential lost of the implant. nonsurgical treatment (deep cleaning with instruments to remove plaque) and rigorous diligent oral care at home are commonly used to treat both periimplantitis (gum disease around an implant) and periodontitis (gum disease around teeth). the medication periochip® is a small dental chip (its size is smaller than a match head, and it is completely flat). the chip contains chlorhexidine gluconate, an antimicrobial agent which is not an antibiotic. the chip is inserted into the gum sulcus that is present around the tooth or implant and biodegrades naturally within 7 to 10 days while releasing the medication. the purpose of this study is to determine the efficacy of periochip® in addition to a standard deep cleaning treatment regime, as compared to standard deep cleaning alone.in a large patient population, and to collect additional safety data about the treatment.

Eligibility criteria:
inclusion criteria: * good general health * at least one implant in the oral cavity with clinical and radiographical signs of peri-implantitis. including bone loss in combination with bleeding and/or suppuration on probing and a peri-implant probing depth (pd) of 5-8 mm. * the implants have been in function for more than 2 years. * fixed prosthetic restoration of the implant. exclusion criteria: * pregnancy. * patient uses chlorhexidine oral rinses/ mouthwashes on a regular basis. * allergic reaction to chlorhexidine. * active periodontitis which required definitive treatment. * presence of orthodontic appliances, or any removable appliances, that impinges on the tissues being assessed. * use of systemic antibiotic therapy and/or chronically use of non-steroidal anti-inflammatory drugs (nsaids). * uncontrolled diabetes, of any type.

Keywords: peri-implantitis periodontal diseases chlorhexidine gluconate periochip anti-infective agents mouth diseases antiseptics
long-term safety study of kw-6002 (istradefylline) in parkinson's disease patients

Conditions: Parkinson's Disease

Summary: patients with parkinson's disease who completed the prior double-blind study 6002-009 are eligible to enter into this long-term study. the purpose of this study is to evaluate the safety and efficacy of kw-6002 administered long-term in patients with advanced parkinson's disease treated with levodopa.


Eligibility criteria:
inclusion criteria: 1. be willing and able to give written informed consent 2. completion of the study 6002-009 exclusion criteria: 1. mini-mental status examination score of 23 or less 2. less than 70% of compliance in the study 6002-009 3. emergency deviation in the study 6002-009 4. pregnant females

Keywords: parkinson's disease levodopa end of dose wearing off off time
diuretic versus placebo in pulmonary embolism

Conditions: Pulmonary Embolism With Right Ventricle Enlargement

Summary: pulmonary embolism (pe) is a frequent and severe disease with an annual incidence of about 75000 cases in france and a short-term mortality rate of about 10%. death is usually related to an acute right ventricular (rv) failure due to the increase in right ventricular afterload. treatment of pe with rv failure consists in fluid expansion and thrombolysis in case of shock. however several studies suggest that fluid expansion may worsen acute rv failure by increasing rv dilatation and ischemia and left ventricular compression by rv dilatation. thus, current guidelines regarding pe treatment remain unclear about the use of fluid expansion. in a preliminary study published by our group, we showed that diuretic treatment in the setting of pe with rv dilatation is safe and is associated with an increase in urine output, a decrease in heart rate and an increase in spo2 in normotensive patients with oliguria. this may be related to the decrease of ventricular interdependence and enhancement of both lv and rv function. the main objective of the study is to evaluate the 24-hours clinical benefit of furosemide in patients referred for acute pe with rv dilatation compared to placebo. the combination of urine output and spesi clinical parameters reflects hemodynamic status. it is relevant as it indicates the disappearance of pre-shock symptoms and is therefore associated with a lower event risk. thus, it allows early discharge of the patients from the intensive care unit.


Eligibility criteria:
inclusion criteria: patients aged 18 years and over with 1. symptomatic acute pulmonary embolism with first clinical symptoms within 15 days, and objectively confirmed by ct scan 2. rv dysfunction (≥1 criterion) confirmed by elevated bnp value or echocardiography or spiral computed tomography of the chest: * echocardiography o right/left ventricular end diastolic diameter \> 1(apical or subcostal 4-chamber view) * computed tomography o right/left short-axis diameter ratio\>0.9 (transverse plane) * positive nt-probnp (\>600) or bnp\>200 pg/ml 3. one abnormal following pesi criteria * heart rate\>110/min * systolic blood pressure\<100mmhg * arterial oxyhemoglobin level\<90% on room air or after 5 minutes of oxygen withdrawal. exclusion criteria: * cardiogenic shock requiring thrombolysis * previous significant left ventricular insufficiency (lvef\<45%) * systolic blood pressure\<90mmhg at admission * age ≤ 18 years * pregnancy * no health insurance * patients deprived of liberty or under legal protection * creatinin clearance \<30ml/min/m² * hypersensibility to furosemide or its excipients * functional renal insufficiency * hepatic encephalopathy * urinary tracks obstruction * hypovolemia or dehydration. * sever hypokalemia (k+ \< 3mmol/l) * severe hyponatremia (na+ \< 125mmol/l) * ongoing hepatitis and hepatic insufficiency severe in patients with renal insufficiency or dialysis

Keywords: pulmonary embolism right ventricle failure diuretics
the steno opti-bolus-timing studies

Conditions: Type 1 Diabetes (T1D)

Summary: the project investigates the significance of the timing of insulin dosing for breakfast and lunch with an automated insulin pump and whether it matters if the meal primarily contains high or low glycemic index carbohydrates. we hypothesise that a bolus given 15 minutes before the meal will result in the best blood glucose levels after the meal, regardless of the type of carbohydrates. participants will attend 6 experimental days over a maximum of 3 months, where they will be served either breakfast or lunch at the research site, depending on sub-study (breakfast or lunch sub-study). three different bolus timings will be tested, with either rapidly absorbed carbohydrates or slowly absorbed carbohydrates, in a randomized order for each participant. participants will take insulin for the meal using the bolus calculator in the pump, either 15 minutes before, at the start of the meal, or 30 minutes after the meal. the development in sensor glucose will then be monitored for up to 4 hours after the meal.


Eligibility criteria:
inclusion criteria: type 1 diabetes ≥ 3 years age 18-70 years user of the minimed 780g for at least 3 months use of novorapid insulin in the pump (for a minimum of two weeks) tir \> 70% for minimum of 14 days use carbohydrate counting and bolus calculation uploads insulin pump and cgm data to the carelink personal database pump settings: carbohydrate ratio (300-500 rule), active insulin time of ≤ 3 hours and smartguard target glucose of 5.5 or 6.1 mmol/l exclusion criteria: use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 4 weeks prior to study start diagnosed with gastroparesis females who are pregnant, breast-feeding food allergies related to standardized meals alcohol or drug abuse inability to understand the individual information and to give informed consent. current participation in another clinical trial that, in the judgment of the principal investigator, will compromise the study results

Keywords: aid system bolus timing glycemic index